Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in…
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represent potential co-primary endpoints to be explored in future trials LONDON and NEW YORK, July10, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative...
Nasdaq GlobeNewswire
10/07/2024
Industrial Bag Dust Filter Market to Grow at 4.7% CAGR, reaching $3.12 Billion…
Workers in heavy-duty sectors are exposed to dust and pollutants that are harmful to the body's respiratory system, which is a key factor driving the demand for industrial bag dust filters. Instances of respiratory issues among workers have been observed in the mining and cement sectors. Governments in several countries such as the United States, Canada, Japan, and others are imposing stringent regulations on these industries, covering environmental concerns, blasting activities, noise, and dust…
PR Newswire
10/07/2024
Clinical Trial Market Size is Expected to Grow at a CAGR of 4.3% and Overpass a…
Both governmental and private sponsorship of clinical trials is helping them increase in number. As the number of diseases and patients increases, there is more demand for research to come up with newer medicines and treatments. The rise in cancer patients is especially necessitating the development of more oncology clinical trials. Both governmental and private sponsorship of clinical trials is helping them increase in number. As the number of diseases and patients increases, there is more...
PR Newswire
10/07/2024
YewMaker - New Playbook Launches to Tackle Global Challenge of Wasted Medicines
Authored by Deloitte and YewMaker, this comprehensive report tackles the critical issue of medicines that are manufactured but never reach patients. Authored by Deloitte and YewMaker, this comprehensive report tackles the critical issue of medicines that are manufactured but never reach patients. Download the full report and start making a difference today : https://www.yewmaker.com/reducing-wasted-medicines-playbook The Crisis of Wasted Medicines Every year, billions of...
PR Newswire
10/07/2024
Orexo AB´s sustainability work ranked among top 5% by EcoVadis
It showcases the outcome of dedicated sustainability activities undertaken over the last several years across social, environmental and governance areas of Orexo AB. And it shows how the employees and partners are working together to achieve successes across four areas: Environment, Labor and Human Rights, Ethics and Sustainable Procurement. It showcases the outcome of dedicated sustainability activities undertaken over the last several years across social, environmental and governance areas of…
PR Newswire
10/07/2024
Nexstim Receives NBS System 5 Order from New European Customer
Press release, Helsinki, 10 July 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from New European Customer Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 through a distributor in Europe. The end customer is acquiring the system primarily for research purposes.The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. The NBS…
Nasdaq GlobeNewswire
10/07/2024
Essential Pharma launches campaign with International Health Partners to donate…
Essential Pharma launches campaign with International Health Partners to donate life-saving medicines to disaster-hit countriesDonations to help support over 30,000 patients in disaster-hit and vulnerable communities worldwide whilst reducing medicine wasteAntibiotics, cardiovascular and mental health drugs cover International Health Partners' (IHP's) signature programmes, maximising patient impactEgham, UK – 10 July, 2024– Essential Pharma, an international specialty pharma...
Nasdaq GlobeNewswire
10/07/2024
Crossject is awarded a 6.9 million euros financing from the French Government…
Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French companies demonstrating outstanding growth and innovation potentialDijon, France, July 10 th, 2024 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the...
Nasdaq GlobeNewswire
10/07/2024
Radioligand Therapies Market to Show Immense Growth by 2034, Predicts…
Key Takeaways from the Radioligand Therapies Market Report Key Takeaways from the Radioligand Therapies Market Report Discover which therapies are expected to grab the radioligand therapies market share @ Radioligand Therapies Market Report Radioligand Therapies Market Dynamics The radioligand therapies market has witnessed significant dynamics driven by advancements in oncology and nuclear medicine. One of the key drivers of market growth is theincreasing incidence of cancer...
PR Newswire
09/07/2024
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, July09, 2024(GLOBE NEWSWIRE) --Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDateNumber of Shares Outstanding Total number of voting rightsTotal voting rights,...
Nasdaq GlobeNewswire
09/07/2024
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et…
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024– GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity...
Nasdaq GlobeNewswire
09/07/2024
ONWARD® Medical Announces Publication Highlighting Evidence-based Programming…
Framework to determine stimulation parameters for ONWARD ARC-EX Therapy are published in the journal Neuromodulation: Technology at the Neural Interface Peer-reviewed publication is based on results from the Up-LIFT and LIFT Home studies EINDHOVEN, the Netherlands, July09, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with...
Nasdaq GlobeNewswire
09/07/2024
Report on Carbios' liquidity contract with Natixis ODDO BHF
PRESS RELEASE REGULATED INFORMATION: ONGOINGReport on Carbios' liquidity contract with Natixis ODDO BHF Shares concerned: Carbios (ISIN code: FR0011648716)Market concerned: Euronext Growth Paris Clermont-Ferrand (France), 09 July 2024 (18:00 CEST).CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, reports today about the liquidity contract...
Nasdaq GlobeNewswire
09/07/2024
IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024
Aggregated presentation by day and by market Purchases of own shares from July 1st to 5th 2024 Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1101/07/2024FR00102591504 400114,6643XPARIPSEN549300M6SGDPB4Z94P1101/07/2024...
Nasdaq GlobeNewswire
09/07/2024
Ipsen - June 2024 - Monthly information relative to the total number of voting…
Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1)30 June 202483,814,526Gross...
Nasdaq GlobeNewswire
09/07/2024
Global Udder Health Market worth $1.6 billion by 2029 driven by Automated…
Browse in-depth TOC on "Udder Health Market" Browse in-depth TOC on "Udder Health Market" 250 - Tables200 - Figures300 - Pages DeLaval ( Sweden ): Leader in Dairy Farming Solutions DeLaval, headquartered in Tumba,Sweden, specializes in dairy farming solutions globally. The company focuses on milking equipment, hygiene products, and farm supplies across over 100 markets, with notable operations in dairy-rich regions like theUSA,Canada, andChina. Acquiring...
PR Newswire
09/07/2024
Medical Biomimetic Market to hit USD 19.3 Billion by 2034 | Report by…
Owing to the growing number of chronic diseases across the world, the scope of the sector is expected to increase. Natural therapies for such chronic diseases are gaining traction in the contemporary world, which drives the demand for biomimetics. Owing to the growing number of chronic diseases across the world, the scope of the sector is expected to increase. Natural therapies for such chronic diseases are gaining traction in the contemporary world, which drives the demand for biomimetics...
PR Newswire
09/07/2024
Epigenetics Market to be Worth $6.33 Billion by 2031 - Exclusive Report by…
Epigenetics is a phenotypic alteration without permanent genotypic change using several methods, including DNA methylation, histone modification, RNA modification, etc. These modifications play a crucial role in diagnosing and prognosis diseases and disorders. Epigenetics finds its major application in oncology due to the global cancer burden and the growing adoption of precision cancer therapies. Epigenetics is a phenotypic alteration without permanent genotypic change using several methods,...
PR Newswire
09/07/2024
Clinion Applauded by Frost & Sullivan for Enabling Interoperability and…
Clinion's eClinical tools capture high-quality patient data, advancing trial operations and boosting the efficiency of clinical development programs. Its cloud-based EDC, RTSM, CTMS, and eCOA integrated platform offer biopharmaceutical sponsors a unified view of trial workflows, thus improving efficiency. The company's AI-enabled eClinical platform employs advanced automation technologies to speed up clinical study timelines and enhance visibility into all aspects of the process. The agile and…
PR Newswire
09/07/2024
Pascal Piedbois, MD, PhD joins One2Treat as Chief Medical Officer to advance…
One2Treat's innovative approach, driven by its Founder Marc Buyse, aims to reduce trial sample sizes and accelerate patient access to new treatments. One2Treat software helps incorporate multiple clinical outcomes that matter to the patient as early as the study design through robust statistical methodologies. Dr. Pascal Piedbois will be a key driver in this endeavor. One2Treat 's innovative approach, driven by its Founder Marc Buyse , aims to reduce trial sample sizes and accelerate...
PR Newswire
09/07/2024
Safe Life Completes Add-On Acquisition in the UK
The new addition in the UK with Defib Store broadens Safe Life's portfolio in the market and the combination of providing AED's and defibrillator cabinets will fortify Safe Life's position as the largest AED specialist provider in the UK. The new addition in the UK with Defib Store broadens Safe Life's portfolio in the market and the combination of providing AED's and defibrillator cabinets will fortify Safe Life's position as the largest AED specialist provider in the UK. "We are excited…
PR Newswire
09/07/2024
SkylineDx Announces All Patients Enrolled in Landmark Study MERLIN_001…
Independent prospective validation is crucial for GEP testing to show its clinical value and establish their cost-effectiveness [2]. Previous prospective data from the Netherlands affirmed the performance metrics published from multiple independent international retrospective cohorts. All of these publications conclude that the Merlin Assay can accurately identify patients at low risk for nodal metastasis. Independent prospective validation is crucial for GEP testing to show its clinical…
PR Newswire
09/07/2024
Pulnovo Medical Announces Joining PHA's (Pulmonary Hypertension Association)…
About PHA About PHA The PHA was founded in 1991 inFloridaand evolved into an international community of more than 16,000 people with PH, caregivers, family members and health care professionals. As one of the largest and oldest pulmonary hypertension association in the world, the PHA acts as a trusted liaison between the pulmonary hypertension community and industry and academic partners. About PADN Pulmonary Artery Denervation (PADN) is a percutaneous pulmonary artery...
PR Newswire
09/07/2024
Univar Solutions Appointed as Exclusive Distributor of VIZOR® Zinc Oxide Sun…
"We are thrilled that VIZOR selected Univar Solutions as its sole distribution partner for Super Zinc powders and dispersion products in Europe. This partnership not only significantly expands our range of sun care ingredients for beauty and personal care purposes, but also demonstrates our commitment to technical innovation ‒ supporting customers who are looking to formulate with top-quality, natural, and eco-friendly ingredients," shared James Peterson, Univar Solutions' global vice…
PR Newswire
09/07/2024
Altri Comunicati
